Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698684 · ClinicalTrials.gov registry record · Phase 4
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
A Phase 4 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 4
- Development phase
- 440
- Enrollment target
NCT01698684 is a Phase 4 study that has completed, run by VIVUS. The registered enrollment target is 440 participants.
The verdict
NCT01698684, a Phase 4 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 440 participants
- Enrollment target
Study Summary
The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction
Interventions
- DRUG Placebo
- DRUG Avanafil 100 mg
- DRUG Avanafil 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698684
The ClinicalTrials.gov registry entry for NCT01698684 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01698684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698684 about?
NCT01698684 is a clinical study titled "Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction". The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction
What is the current status of trial NCT01698684?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 440 participants. The study started on 2012-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01698684?
The interventions under investigation include: Placebo (DRUG), Avanafil 100 mg (DRUG), Avanafil 200 mg (DRUG).
Who is sponsoring clinical trial NCT01698684?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.